Maria Andersen

ORCID: 0000-0003-2883-2450
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Head and Neck Cancer Studies
  • Lung Cancer Treatments and Mutations
  • Head and Neck Surgical Oncology
  • Mass Spectrometry Techniques and Applications
  • Lung Cancer Diagnosis and Treatment
  • Ear and Head Tumors
  • Prostate Cancer Treatment and Research
  • Cancer Diagnosis and Treatment
  • Cancer, Lipids, and Metabolism
  • Metabolomics and Mass Spectrometry Studies
  • Salivary Gland Tumors Diagnosis and Treatment
  • Advanced Radiotherapy Techniques
  • Sinusitis and nasal conditions
  • Radiomics and Machine Learning in Medical Imaging
  • Advanced Proteomics Techniques and Applications
  • Oral and Maxillofacial Pathology
  • Cholesterol and Lipid Metabolism
  • Esophageal Cancer Research and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Oral health in cancer treatment
  • Cancer-related molecular mechanisms research
  • Tumors and Oncological Cases
  • Medical Imaging Techniques and Applications
  • Cryospheric studies and observations
  • Immune cells in cancer

Aalborg University Hospital
2009-2024

Norwegian University of Science and Technology
2017-2024

St Olav's University Hospital
2024

NTNU Samfunnsforskning
2022

China Medical University
2019

China Medical University Hospital
2019

Frederiksberg Hospital
2014

Aalborg University
2013

Moelven (Norway)
2007

Odense University Hospital
1988

Barbara Burtness Kevin J. Harrington Richard Greil Denis Soulières Makoto Tahara and 95 more Gilberto de Castro Amanda Psyrri Neus Basté Prakash Neupane Åse Bratland Thorsten Fuereder Brett Hughes Ricard Mesı́a Nuttapong Ngamphaiboon Tamara Rordorf Wan Zamaniah Wan Ishak Ruey‐Long Hong René González Mendoza Ananya Roy Yayan Zhang Burak Gümüşçü Jonathan D. Cheng Fan Jin Danny Rischin Guillermo Lerzo Marcelo Tatangelo Mirta Varela Juan José Zarbá Michael Boyer Hui Gan Bo Gao Brett Hughes Girish Mallesara Danny Rischin Anne L. Taylor Martin Burian Thorsten Fuereder Richard Greil Carlos H. Barrios Gilberto de Castro Gilberto de Castro Fábio Franke Gustavo Girotto Iane Pinto Figueiredo Lima Ulisses Ribaldo Nicolau Gustavo Dix Junqueira Pinto Lucas Vieira dos Santos Ana-Paula Victorino Neil Chua Félix Couture Richard Gregg Aaron R. Hansen John Hilton Joy McCarthy Denis Soulières Rodrigo Ascuí Pablo Gonzalez Luis J. Villanueva-Rivera Marco Torregroza Ángela R. Zambrano Petra Beran Holečková Zdeněk Král Bohuslav Melichar Prausova Jana Milan Vošmik Maria Andersen Niels Gyldenkerne Hannes Jürgens Kadri Putnik Petri Reinikainen Viktor Gruenwald Simon Laban Gerasimos Aravantinos Ioannis Boukovinas Vassilis Georgoulias Amanda Psyrri D.L.W. Kwong Yousuf Al-Farhat Tibor Csőszi József Erfán Geza Horvai László Landherr Éva Remenár Ágnes Ruzsa Judit Szota Salem Billan Iris Gluck Orit Gutfeld Aron Popovtzer Marco Benasso Simona Bui Vittorio Ferrari Lisa Licitra Franco Nolè Takashi Fujii Yasushi Fujimoto Nobuhiro Hanai Hiroki Hara Koji Matsumoto Kenji Mitsugi

10.1016/s0140-6736(19)32591-7 article EN The Lancet 2019-11-01

Abstract Background Prostate cancer tissues are inherently heterogeneous, which presents a challenge for metabolic profiling using traditional bulk analysis methods that produce an averaged profile. The aim of this study was therefore to spatially detect metabolites and lipids on prostate tissue sections by mass spectrometry imaging (MSI), method facilitates molecular heterogeneous sections, can subsequently be related the histology same section. Methods Here, we simultaneously obtained...

10.1186/s40170-021-00242-z article EN cc-by Cancer & Metabolism 2021-01-29

Abstract Reactive stroma is a tissue feature commonly observed in the tumor microenvironment of prostate cancer and has previously been associated with more aggressive tumors. The aim this study was to detect differentially expressed genes metabolites according reactive content measured on exact same sample. evaluated using histopathology from 108 fresh frozen samples gathered 43 patients after prostatectomy (Biobank1). A subset analyzed both for metabolic (n = 85) transcriptomic alterations...

10.1038/s41598-018-32549-1 article EN cc-by Scientific Reports 2018-09-18

AbstractThe present study comprises 847 women operated upon for invasive breast carcinoma at 19 surgical departments and enrolled in protocol DBCG-82TM from January 1983 to November 1987. Among them 662 (78%) were allocated breast-preserving therapy or mastectomy by randomization, while 185 patients (22%) did not accept randomization. Within the randomized group 6% could be entered into adjuvant protocols, i.e. subsequent programmes of postoperative follow-up. This left 619 evaluable...

10.3109/02841868809091767 article EN Acta Oncologica 1988-01-01

Objective. To evaluate the treatment outcome for sino-nasal carcinomas in Denmark from 1995–2004 and compare results to previous Danish survey covering 1982–1991. Design. Retrospective follow-up. Materials methods. In five head neck oncology centres, charts of all consecutive patients with were reviewed data extracted a common database. Altogether 242 period identified. Of these 162 (67%) male 80 (33%) female. Histologies included squamous cell carcinoma (55%), adenocarcinoma (28.5%),...

10.3109/02841860903428176 article EN Acta Oncologica 2009-12-10

MALDI MS imaging (MSI) is a powerful analytical tool for spatial peptide detection in heterogeneous tissues. Proper sample preparation crucial to achieve high quality, reproducible measurements. Here we developed an optimized protocol spatially resolved proteolytic with time-of-flight MSI of fresh frozen prostate tissue sections. The parameters tested included four different washes, methods protein denaturation, trypsin digestion (different densities, sprayers, and incubation times), five...

10.1002/pmic.202100223 article EN PROTEOMICS 2022-02-16

Reliable and accessible biomarkers for patients with Head Neck Squamous Cell Carcinoma (HNSCC) are warranted biologically driven radiotherapy (RT). This study aimed to investigate the prognostic value of putative cancer stem cell (CSC) markers, hypoxia, tumor volume using loco-regional high-dose failure (HDF) as endpoint.

10.1016/j.radonc.2024.110149 article EN cc-by Radiotherapy and Oncology 2024-02-09

Abstract Prostate cancer treatment resistance is a significant challenge facing the field. Genomic and transcriptomic profiling have partially elucidated mechanisms through which cells escape treatment, but their relation toward tumor microenvironment (TME) remains elusive. Here we present comprehensive landscape of prostate TME at multiple points in standard timeline employing single-cell RNA-sequencing spatial transcriptomics data from 120 patients. We identify club-like as key epithelial...

10.1038/s41467-024-54364-1 article EN cc-by Nature Communications 2024-11-16

Levels of zinc, along with its mechanistically related metabolites citrate and aspartate, are widely reported as reduced in prostate cancer compared to healthy tissue therefore pointed out potential biomarkers. Previously, it has only been possible analyze zinc by separate detection methods. Through matrix-assisted laser desorption/ionization mass spectrometry imaging (MSI), we were for the first time able demonstrate, two different sample sets (n = 45 n 4), simultaneous spatial form ZnCl3–,...

10.1021/acs.analchem.9b04903 article EN cc-by Analytical Chemistry 2020-01-16

Abstract To truly understand the cancer biology of heterogenous tumors in context precision medicine, it is crucial to use analytical methodology capable capturing complexities multiple omics levels, as well spatial heterogeneity tissue. Different molecular imaging techniques, such mass spectrometry (MSI) and transcriptomics (ST) achieve this goal by spatially detecting metabolites mRNA, respectively. take full advantage multi-omics data, individual measurements need be integrated into one...

10.1101/2024.06.11.598306 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2024-06-12

Background. The post-treatment follow-up is well-integrated in the oncologic care tradition, based on risk of developing recurrent disease or new primary tumors treated patients. Furthermore, serves as an opportunity to monitor treatment effects and provide clinical side effects. In this study we measured activity effectiveness routine head neck cancer assessed value from perspectives both physicians Patients methods. During a period six weeks prospective national cross section cohort 619...

10.3109/0284186x.2012.741324 article EN Acta Oncologica 2013-01-16

Introduction: Prediction models using logistic regression may perform poorly in external patient cohorts. However, there is a need to standardize and validate for clinical use. The purpose of this project was describe method validation NTCP used selection the randomized trial protons versus photons head neck cancer radiotherapy, DAHANCA 35.Material methods: Organs at risk 588 patients treated primarily with IMRT controlled DAHANCA19 were retrospectively contoured according recent...

10.1080/0284186x.2019.1654129 article EN Acta Oncologica 2019-08-21

Abstract Background Truly understanding the cancer biology of heterogeneous tumors in precision medicine requires capturing complexities multiple omics levels and spatial heterogeneity tissue. Techniques like mass spectrometry imaging (MSI) transcriptomics (ST) achieve this by spatially detecting metabolites RNA but are often applied to serial sections. To fully leverage advantage such multi-omics data, individual measurements need be integrated into 1 dataset. Results We present Multi-Omics...

10.1093/gigascience/giaf035 article EN cc-by GigaScience 2025-01-01

Background: The study aimed to evaluate Hyperfractionated, Accelerated Radiotherapy (HART) with nimorazole for patients head and neck squamous cell carcinoma (HNSCC) using loco-regional failure (LRF), overall survival (OS), early late morbidity as endpoints.Material methods: From February 2007 January 2018, 295 unresected HNSCC, T1-T4, N0-N3, M0, were treated HART prescribed 76 Gy in 56 fractions (fx), 10 fx weekly. IMRT was used >90% of patients. No chemotherapy given. Patients...

10.1080/0284186x.2019.1658897 article EN Acta Oncologica 2019-09-13

AbstractBackground In the Danish Head and Neck Cancer Group (DAHANCA) 35 trial, patients are selected for proton treatment based on simulated reductions of Normal Tissue Complication Probability (NTCP) compared to photon at referring departments. After inclusion in immobilization, scanning, contouring planning repeated national centre. The new contours could result reduced expected NTCP gain plan, resulting a loss validity selection process. present study evaluates if contour consistency can...

10.1080/0284186x.2023.2256958 article EN Acta Oncologica 2023-09-13

IntroductionPatients with failure after primary radiotherapy (RT) for head and neck squamous cell carcinoma (HNSCC) have a poor prognosis. This study investigates pattern of curatively intended IMRT in randomized controlled trial relation to HPV/p16 status.Material methodsPatients HNSCC the oral cavity, oropharynx (OPSCC), hypopharynx or larynx were treated curative (±cisplatin) concomitant nimorazole between 2007 12. Of 608 patients, 151 had loco-regional within five years, from whom 130...

10.1016/j.ctro.2024.100772 article EN cc-by-nc-nd Clinical and Translational Radiation Oncology 2024-03-30

Prostate tumor heterogeneity is a major obstacle when studying the biological mechanisms of molecular markers. Increased gene expression levels secreted frizzled-related protein 4 (SFRP4) biomarker in aggressive prostate cancer. To understand how SFRP4 relates to cancer we performed comprehensive spatial and multiomics analysis same tissue samples. The experimental workflow included transcriptomics, bulk proteomics, DNA methylomics staining. mRNA was predominantly located stroma, produced by...

10.1038/s42003-024-07161-x article EN cc-by Communications Biology 2024-11-08

Increased knowledge of the molecular differences between indolent and aggressive prostate cancer is needed for improved risk stratification treatment selection. Secreted frizzled-related protein 4 (SFRP4) a modulator cancer-associated Wnt pathway, previously suggested as potential marker aggressiveness. In this study, we investigated validated association SFRP4 gene expression aggressiveness in nine independent cohorts (n = 2157). By differential combined meta-analysis all cohorts, detected...

10.1038/s41598-017-14622-3 article EN cc-by Scientific Reports 2017-10-23

Altered metabolism is one of the key molecular characteristics prostate cancer (PCa) development, and a number studies have searched for metabolic biomarkers in patient-derived samples. Reported changes PCa tissue compared with normal include reduced levels citrate spermine, elevated lipid synthesis fatty acid oxidation, higher amino acids alanine, glutamine, glutamate. Recent investigated tumor microenvironment, such as reactive stroma, so-called field effects. Furthermore, analysis blood...

10.1016/j.coemr.2020.02.003 article EN cc-by Current Opinion in Endocrine and Metabolic Research 2020-02-01
Coming Soon ...